The Impact of Early Belimumab Use on Successful Glucocorticoid Tapering to a Low Maintenance Dose in Treatment‐naïve, Newly Diagnosed Systemic Lupus Erythematosus
International Journal of Rheumatic Diseases · 2025
DOI: 10.1111/1756-185x.70462 ↗Kurz gefasst
Fachartikel in der Zeitschrift International Journal of Rheumatic Diseases, 2025. Verfasst von Takehiro Nakai und 6 weiteren Autor:innen. Beteiligte Einrichtung: Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan. Hauptthemen laut MEDLINE: Lupus Erythematosus, Systemic, Immunosuppressive Agents, Glucocorticoids, Antibodies, Monoclonal, Humanized. Die Arbeit nennt 41 Literaturangaben.
Abstract (Originalsprache)
Objectives
Glucocorticoids rapidly control inflammation in systemic lupus erythematosus (SLE), yet prolonged use contributes to organ damage and increased mortality. Optimal tapering strategies in newly diagnosed, treatment‐naïve patients remain unclear. This study aimed to identify predictors for glucocorticoid tapering, focusing on early belimumab initiation and the safety of high‐dose induction therapy.
Methods
We retrospectively studied newly diagnosed, treatment‐naïve SLE patients initiated on prednisolone (PSL) > 20 mg/day between April 2006 and April 2024. Early belimumab exposure was defined as initiation of therapy within 26 weeks of diagnosis with continuation for at least 26 weeks. Kaplan–Meier analysis determined the time to achieve PSL ≤ 7.5 mg/day and ≤ 5 mg/day. Cox proportional hazards models identified factors associated with early tapering.
Results
Of 537 patients, 106 met the inclusion criteria. The median initial PSL dose was 50.0 mg/day (IQR: 30.0–75.0), tapering to 5.00 mg/day (IQR: 3.00–7.62) by week 52. Early belimumab exposure was significantly associated with tapering to ≤ 7.5 mg/day (HR 4.05, 95% CI: 1.95–8.38, p < 0.001) and showed a trend toward achieving ≤ 5 mg/day. Patients with early belimumab exposure also had significantly higher LLDAS attainment (HR 4.07, CI 1.97–8.43, p < 0.001). High‐dose induction (PSL > 40 mg/day) and rapid tapering were not associated with delayed tapering or increased cumulative exposure.
Conclusion
Early belimumab initiation was associated with glucocorticoid tapering and higher LLDAS attainment in treatment‐naïve SLE patients, potentially reducing long‐term steroid‐related risks. High‐dose glucocorticoid induction therapy and rapid tapering approaches appear safe without increasing cumulative glucocorticoid exposure, supporting their consideration in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Immuno-Rheumatology Center, St. Luke's International Hospital, Tokyo, Japan.
- Division of Rheumatology, Inflammation, and Immunity, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts, USA.
- Department of Emergency and General Medicine, Kyorin University School of Medicine, Tokyo, Japan.
- Department of Rheumatology, Suwa Central Hospital, Nagano, Japan.
- Department of Nephrology and Rheumatology, Kyorin University School of Medicine, Tokyo, Japan.
ORCID-Profile: Takehiro Nakai, Sho Fukui
Zitieren
APA
Nakai, T., Fukui, S., Ikeda, Y., Suda, M., Tamaki, H., Kishimoto, M., & Okada, M. (2025). The Impact of Early Belimumab Use on Successful Glucocorticoid Tapering to a Low Maintenance Dose in Treatment‐naïve, Newly Diagnosed Systemic Lupus Erythematosus. International Journal of Rheumatic Diseases. https://doi.org/10.1111/1756-185x.70462
Vancouver
Nakai T, Fukui S, Ikeda Y, Suda M, Tamaki H, Kishimoto M, et al. The Impact of Early Belimumab Use on Successful Glucocorticoid Tapering to a Low Maintenance Dose in Treatment‐naïve, Newly Diagnosed Systemic Lupus Erythematosus. International Journal of Rheumatic Diseases. 2025. doi:10.1111/1756-185x.70462
BibTeX
@article{Nakai2025,
author = {Nakai, Takehiro and Fukui, Sho and Ikeda, Yukihiko and Suda, Masei and Tamaki, Hiromichi and Kishimoto, Mitsumasa and Okada, Masato},
title = {The Impact of Early Belimumab Use on Successful Glucocorticoid Tapering to a Low Maintenance Dose in Treatment‐naïve, Newly Diagnosed Systemic Lupus Erythematosus},
journal = {International Journal of Rheumatic Diseases},
year = {2025},
doi = {10.1111/1756-185x.70462}
}
EUVIMED